DYNE THERAPEUTICS DL-0001

Dyne Therapeutics' stock rose to a new 52-week high of $27.19 and most recently has a market capitalization of about $5 billion with a one-year return of nearly 130%. The company placed a public offering of $375 million at $20.50 per share (a 14% discount) and announced a further offering of $300 million with a $45 million greenshoe option. The FDA accepted the regulatory application for rostudirsen (Zeleciment) for review and granted Priority Review with a target action date of January 21, 2027; analysts including Cantor Fitzgerald and TD Cowen initiated with positive ratings, while an InvestingPro valuation points to possible overvaluation. » Plus sur de.investing.com

The FDA approved the IND for DYNE‑302, allowing Dyne Therapeutics to start a randomized, double‑blind, placebo‑controlled phase‑1 study in ambulatory adults with facioscapulohumeral muscular dystrophy (FSHD). DYNE‑302 uses a TfR1‑targeting Fab fragment to deliver an siRNA designed to suppress DUX4 expression in skeletal muscle; preclinically, the treatment produced DUX4 knockdown, reversal of muscle fiber pathology and functional improvements. The study's primary endpoint is safety and tolerability; PK/PD, changes in the DUX4 transcriptome and KHDC1L plasma levels will also be assessed. Dyne plans to evaluate higher doses subsequently, offer an extension study up to 96 weeks and pursue a traditional regulatory pathway in the US. » Plus sur de.investing.com

Dyne Therapeutics placed an upsized public offering of 18.3 million common shares at $20.50 each, representing a discount of about 14% to the closing price and expected to generate gross proceeds of roughly $375.15 million. The news triggered a premarket share decline, amplified by recent insider sales of 777,451 shares and a weak market environment. Bookrunners were granted a 30-day overallotment option, and the deal is expected to close around July 23, 2026. Although the capital raise strengthens the balance sheet, investors view the near-term dilution and large discount negatively. » Plus sur de.investing.com